Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV)
Infectious Disease Reports · 25.04.2023 · 15 (3) · 231-237
DOI: 10.3390/idr15030024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infectious Disease Reports, online erschienen am 25.04.2023. Verfasst von Anne M Masich und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Virginia Commonwealth University Health, Richmond, VA 23298, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A drug-drug interaction (DDI) exists between bictegravir and metformin. Bictegravir inhibits renal organic cation transporter-2, leading to increased metformin plasma concentrations. The objective of this analysis was to evaluate the clinical implications of concomitant bictegravir and metformin administration. This was a retrospective, single-center, descriptive analysis evaluating people with human immunodeficiency virus (PWH) concurrently prescribed bictegravir and metformin between February 2018–June 2020. PWH lost to follow-up or non-adherent were excluded. Data collection included: hemoglobin A1C (HgbA1C), HIV RNA viral load, CD4 cell count, serum creatinine, and lactate. Adverse drug reactions (ADRs) were assessed by provider-documented, patient-reported symptoms of gastrointestinal (GI) intolerance and hypoglycemia. Metformin dose adjustments and discontinuations were recorded. Fifty-three PWH were included (116 screened; 63 excluded). GI intolerance was reported in three PWH (5.7%). There were no documented episodes of hypoglycemia or lactic acidosis. Five PWH had metformin dose reductions (N = 3 for unspecified reasons; N = 1 for GI intolerance) or discontinuation (N = 1 unrelated to ADRs). Both diabetes and HIV control improved (HgbA1C decreased by 0.7% with virologic control in 95% of PWH). Minimal ADRs were reported in PWH receiving concurrent metformin and bictegravir. Prescribers should be aware of this potential interaction; however, no empiric metformin total daily dose adjustment appears necessary.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Virginia Commonwealth University Health, Richmond, VA 23298, USA.
- Department of Pharmacotherapy and Outcome Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Department of Internal Medicine, Division of Infectious Diseases, Virginia Commonwealth University Health, Richmond, VA 23298, USA.
ORCID-Profile: Patricia P Fulco
Zitieren
APA
Masich, A. M., Thompson, L., & Fulco, P. P. (2023). Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV). Infectious Disease Reports, 15(3), 231-237. https://doi.org/10.3390/idr15030024
Vancouver
Masich AM, Thompson L, Fulco PP. Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV). Infectious Disease Reports. 2023;15(3):231-237. doi:10.3390/idr15030024
BibTeX
@article{Masich2023,
author = {Masich, Anne M and Thompson, Lindsey and Fulco, Patricia P},
title = {Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV)},
journal = {Infectious Disease Reports},
year = {2023},
volume = {15},
number = {3},
pages = {231--237},
doi = {10.3390/idr15030024}
}
EUVIMED